Invivyd, Inc. · NASDAQ:IVVD
Invivyd — Investor Presentation (January 2024)
18 slides from Invivyd's investor presentation, Jan 8, 2024
Slide 1: Corporate Overview
Exhibit 99.1 CORPORATE OVERVIEW January 8, 2024 © 2024 Invivyd, Inc. Invivyd and the Invivyd logo are trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners.
Slide 2: Cautionary Note Regarding Forward-Looking Statements
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words
Slide 3: Invivyd is poised to enter a transformational period
INVIVYD IS POISED TO ENTER A TRANSFORMATIONAL PERIOD, WITH A NEAR-TERM OPPORTUNITY TO DELIVER A MUCH NEEDED THERAPEUTIC • In January 2024, Invivyd announced the submission of a request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222 for the pre-exposure prevention of COVID-19 in immunoc
Slide 4: Mission to rapidly deliver antibodies protecting vulnerable populations from viral threats
INVIVYD IS ON A MISSION TO RAPIDLY DELIVER ANTIBODIES THAT PROTECT VULNERABLE POPULATIONS FROM VIRAL THREATS, STARTING WITH COVID-19 Near-Term Opportunity >9M Zero EUA pathway provides the potential immunocompromised people authorized or approved opportunity to rapidly bring in the U.S. alone who ma
Slide 5: Many immunocompromised people have impaired immune response to COVID-19 vaccines
MANY IMMUNOCOMPROMISED PEOPLE HAVE AN IMPAIRED IMMUNE RESPONSE TO COVID-19 VACCINES Immunocompromised people are less likely to have detectable SARS-CoV-2 antibodies following vaccination than immunocompetent people 1 Seroconversion rates (detectable Abs) in immunocompromised people vs. immunocompet
Slide 6: Despite vaccination, immunocompromised people remain at higher risk for severe COVID-19
DESPITE VACCINATION, IMMUNOCOMPROMISED PEOPLE REMAIN AT HIGHER RISK FOR SEVERE COVID-19 OUTCOMES 1 The recent INFORM study, conducted during the Omicron period, found that in a sample of nearly 12 million people: Immunocompromised (IC) people represented only IC individuals accounted for IC individu
Slide 7: Significant market opportunity with >9M immunocompromised people in the U.S.
SIGNIFICANT MARKET OPPORTUNITY WITH >9M IMMUNOCOMPROMISED PEOPLE AT INCREASED RISK FOR SEVERE COVID-19 IN THE U.S. Estimated U.S. total addressable market (TAM) for PrEP • Of the estimated 485K High immunocompromised (IC) people at highest risk: 485K – 67K: stem cell transplants 2M – 86K: solid orga
Slide 8: Monoclonal antibodies have potential in prevention and treatment of COVID-19
IN ADDITION TO PREVENTION, MONOCLONAL ANTIBODIES ALSO HAVE COMPELLING POTENTIAL IN THE TREATMENT OF COVID-19 PREVENTION TREATMENT Vaccines mAbs Antivirals Anti-SARS-CoV-2 mAbs are expected to provide: • Rapid, passive immunity Limitations for the Limitations for the immunocompromised: • Utility for
Slide 9: Our Platform & VYD222
Our Platform & VYD222 © 2024 Invivyd, Inc. Invivyd and the Invivyd logo are trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners.
Slide 10: INVYMAB platform approach for rapid, serial generation of new antibodies
INVYMAB™ PLATFORM APPROACH IS DESIGNED FOR RAPID, SERIAL GENERATION OF NEW ANTIBODIES TO ADDRESS VIRAL THREATS The company’s proprietary INVYMAB platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody discovery and engineering VIRAL SURVEILLANCE
Slide 11: VYD222: candidate for pre-exposure prevention of COVID-19
VYD222: A CANDIDATE FOR THE PRE-EXPOSURE PREVENTION OF COVID-19 IN IMMUNOCOMPROMISED ADULTS AND ADOLESCENTS Ph 2/3 clinical trial of ADG20 for COVID-19 prevention RBD Spike ACE2 Ph 2/3 clinical trial of ADG20 for COVID-19 treatment Broadly neutralizing, half-life extended Binds to the spike protein
Slide 12: VYD222 broad in vitro neutralizing activity against variants
VYD222 HAS DEMONSTRATED BROAD IN VITRO NEUTRALIZING ACTIVITY AGAINST VARIOUS PRE-OMICRON AND OMICRON VARIANTS 1 VARIANT SUBLINEAGE VYD222 WT(D614G) WT(D614G) ✓ Delta B.1.617.2 ✓ BA.4.6 ✓ BF.7 ✓ XBB.1 ✓ XBB.1.5 ✓ XBB.1.16 ✓ Omicron XBB.1.5.10/EG.5 ✓ HK.3 ✓ BA.2.86 ✓ HV.1 ✓ JN.1 is currently the domin
Slide 13: Invivyd rapidly advancing VYD222 for pre-exposure prevention
INVIVYD IS RAPIDLY ADVANCING VYD222 FOR THE PRE-EXPOSURE PREVENTION OF COVID-19 IN IMMUNOCOMPROMISED ADULTS AND ADOLESCENTS Ph 1 to EUA submission in ~9 months Reported Dosed first Reported Dosed first positive initial participants in positive initial participant in Ph 1 trial Ph 1 data Ph 3 pivotal
Slide 14: VYD222 EUA submission based on positive initial Phase 3 results
VYD222 EUA SUBMISSION IS BASED ON POSITIVE INITIAL RESULTS FROM THE ONGOING PHASE 3 VYD222 CLINICAL TRIAL (CANOPY) VYD222 4500 mg IV (n≈300) Initial CANOPY results reported COHORT A Open Label in December 2023: Immunocompromised // (N≈300) Day 1 Month 3 Month 12 • VYD222 produced high sVNA (Dosing)
Slide 15: If authorized, aims to have VYD222 commercially available rapidly
IF AUTHORIZED, INVIVYD AIMS TO HAVE VYD222 COMMERCIALLY AVAILABLE IN THE U.S. RAPIDLY THEREAFTER Commercial preparations are being led by a seasoned team with extensive experience successfully commercializing products within the infectious disease space Preparations completed or underway: Go-to-mark
Slide 16: VYD222 is one of many antibodies in Invivyd's pipeline
VYD222 IS ONE OF MANY ANTIBODIES IN INVIVYD'S PIPELINE DISCOVERY/ PROGRAMS PLATFORM INDICATION(S) IND-ENABLING PHASE 1 PHASE 2 PHASE 3 STATUS PRECLINICAL SARS-COV-2 Reported positive initial Pre-exposure VYD222 mAb Ph 3 results and submitted prevention EUA request COVID Prevention or Engineering var
Slide 17: Management team with expertise in infectious diseases
MANAGEMENT TEAM WITH EXPERTISE IN INFECTIOUS DISEASES AND TRACK RECORD OF SUCCESS Peter C. Schmidt, M.D., MSc Stacy Price, M.S. William Duke, M.B.A Dave Hering, M.B.A. Chief Medical Officer Chief Technology & Manufacturing Officer Chief Financial Officer Chief Executive Officer & Director Jill Ander
Slide 18: Thank You!
THANK YOU!